Impax Asset Management Group plc Acquires 5,106 Shares of Edwards Lifesciences Corporation $EW

Impax Asset Management Group plc grew its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 28.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 23,175 shares of the medical research company’s stock after purchasing an additional 5,106 shares during the period. Impax Asset Management Group plc’s holdings in Edwards Lifesciences were worth $1,813,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Brighton Jones LLC bought a new stake in shares of Edwards Lifesciences during the fourth quarter valued at approximately $266,000. CWM LLC increased its stake in Edwards Lifesciences by 36.3% during the 1st quarter. CWM LLC now owns 32,916 shares of the medical research company’s stock valued at $2,386,000 after purchasing an additional 8,772 shares in the last quarter. Signaturefd LLC raised its holdings in Edwards Lifesciences by 11.5% during the first quarter. Signaturefd LLC now owns 6,202 shares of the medical research company’s stock worth $450,000 after buying an additional 638 shares during the last quarter. Sigma Planning Corp lifted its stake in shares of Edwards Lifesciences by 4.9% in the first quarter. Sigma Planning Corp now owns 4,055 shares of the medical research company’s stock valued at $294,000 after buying an additional 191 shares in the last quarter. Finally, Apollon Wealth Management LLC lifted its stake in shares of Edwards Lifesciences by 8.9% in the first quarter. Apollon Wealth Management LLC now owns 7,916 shares of the medical research company’s stock valued at $574,000 after buying an additional 645 shares in the last quarter. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Stock Performance

NYSE:EW opened at $86.17 on Friday. The stock has a market cap of $50.00 billion, a P/E ratio of 12.40, a PEG ratio of 3.97 and a beta of 1.03. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. The business’s 50-day moving average price is $78.09 and its two-hundred day moving average price is $77.65. Edwards Lifesciences Corporation has a twelve month low of $65.31 and a twelve month high of $87.21.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. The business had revenue of $1.55 billion for the quarter, compared to analysts’ expectations of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The firm’s revenue was up 14.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.67 earnings per share. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. As a group, equities analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on EW. Piper Sandler reissued an “overweight” rating and set a $95.00 price objective (up from $90.00) on shares of Edwards Lifesciences in a report on Friday, October 31st. The Goldman Sachs Group set a $104.00 price target on Edwards Lifesciences and gave the stock a “buy” rating in a report on Friday, October 31st. Wall Street Zen lowered Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a research report on Monday, September 29th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a report on Wednesday, October 8th. Finally, Barclays reissued an “overweight” rating and set a $99.00 target price (up previously from $95.00) on shares of Edwards Lifesciences in a research report on Friday, October 31st. Three research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $91.39.

Insider Activity at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 1,020 shares of the stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $82.55, for a total transaction of $84,201.00. Following the completion of the sale, the vice president owned 22,002 shares of the company’s stock, valued at approximately $1,816,265.10. This represents a 4.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Larry L. Wood sold 8,950 shares of the firm’s stock in a transaction on Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the sale, the insider directly owned 206,900 shares in the company, valued at approximately $16,150,614. This trade represents a 4.15% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 22,970 shares of company stock worth $1,862,878 in the last ninety days. 0.34% of the stock is owned by company insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.